Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

NCT00418132 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Study terminated early due to difficulties in subject recruitment

Conditions

Scleroderma, Systemic

Interventions

DRUG: Thalidomide
DRUG: Placebo thalidomide

Sponsor

NYU Langone Health

Collaborators

[object Object]